APOB and Alzheimer disease: In individuals with high TGs with and without AD treated with at least moderate-intensity statin, the addition of evolocumab (Q2W or QM), compared to placebo, significantly reduced mean LDL-C by 66.7% to 74.3%, non-HDL-C by 53.4% to 65.8%, and ApoB by 41.5% to 56.6% (all P-values < 0.0001).